Clinical trial / 2020
Broccoli sprout capsules did not significantly alter 180-day survival in pancreatic cancer
Forty patients receiving palliative chemotherapy were placed unblinded into a treatment group (n = 29, receiving 15 daily capsules of pulverized broccoli sprouts) or placebo group (n = 11, receiving methylcellulose) for up to 1 year. The mean death rate was lower in the treatment group in the first 6 months (day 30: 0% vs 18%, day 90: 0% vs 25%, day 180: 25% vs 43%), but the endpoint at day 180 was not statistically significant (p = 0.291). Dropout rates after 1 year were high (72% treatment, 55% placebo). Taking 15 daily capsules was difficult for some patients, and the sprouts sometimes increased digestive problems, nausea, and emesis.
- Study type
- Unblinded controlled pilot trial
- Who was studied
- 40 patients with advanced pancreatic cancer on palliative chemotherapy
- What was measured
- Patient characteristics, overall survival, and feasibility
THE PAPER
Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects-results from the POUDER pilot study.
Lozanovski VJ, Polychronidis G, Gross W, Gharabaghi N, Mehrabi A, Hackert T, Schemmer P, Herr I. Invest New Drugs, 2020.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.